Finally, Programmed Death Ligand 1 (PD-L1), which demonstrated a prognostic and predictive role in BC [32,33], is an important target of some immunotherapies, such as Atezolizumab, which has been approved for the treatment of PD-L1 positive metastatic triple negative BC [34]. The gene discussed is CD274; the disease is breast cancer.